Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting. by Berkowitz, J. C. et al.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2018
Declining use of combination infliximab and
immunomodulator for inflammatory bowel disease
in the community setting.
J. C. Berkowitz
Northwell Health
J. Stein-Fishbein
S. Khan
R. Furie
Zucker School of Medicine at Hofstra/Northwell
K. S. Sultan
Zucker School of Medicine at Hofstra/Northwell
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Gastroenterology Commons
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.
Recommended Citation
Berkowitz JC, Stein-Fishbein J, Khan S, Furie R, Sultan KS. Declining use of combination infliximab and immunomodulator for
inflammatory bowel disease in the community setting.. . 2018 Jan 01; 9(1):Article 4284 [ p.]. Available from:
https://academicworks.medicine.hofstra.edu/articles/4284. Free full text article.
300 Community Dr., Manhasset, NY 11030, 
United States. ksultan@northwell.edu
Telephone: +1-516-3873990
Fax: +1-516-3873930
Received: March 20, 2017
Peer-review started: March 23, 2017
First decision: May 3, 2017
Revised: August 2, 2017
Accepted: November 9, 2017
Article in press: November 9, 2017
Published online: February 6, 2018 
Abstract
AIM
To describe trends of combination therapy (CT) of in-
fliximab (IFX) and immunomodulator (IMM) for inflam-
matory bowel disease (IBD) in the community setting. 
METHODS
A retrospective study was conducted of all IBD patients 
referred for IFX infusion to our community infusion center 
between 04/01/01 and 12/31/14. CT was defined as use 
of IFX with either azathioprine, 6-mercaptopurine, or 
methotrexate. We analyzed trends of CT usage overall, 
for Crohn’s disease (CD) and ulcerative colitis (UC), 
and for the subgroups of induction patients. We also 
analyzed the trends of CT use in these groups over the 
study period, and compared the rates of CT use prior to 
and after publication of the landmark SONIC trial.
RESULTS 
Of 258 IBD patients identified during the 12 year study 
period, 60 (23.3%) received CT, including 35 of 133 
(26.3%) induction patients. Based on the Cochran-
Armitage trend test, we observed decreasing CT use 
for IBD patients overall (P  < 0.0001) and IBD induction 
patients, (P  = 0.0024). Of 154 CD patients, 37 (24.68%) 
had CT, including 20 of 77 (26%) induction patients. 
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Retrospective Study
The Cochran Armitage test showed a trend towards 
decreasing CT use for CD overall (P  < 0.0001) and CD 
induction, (P  = 0.0024). Overall, 43.8% of CD patients 
received CT pre-SONIC vs  7.4% post-SONIC (P  < 
0.0001). For CD induction, 40.0% received CT pre-
SONIC vs  10.8% post-SONIC (P  = 0.0035). Among the 
93 patients with UC, 19 (20.4%) received CT. Of 50 
induction patients, 14 (28.0%) received CT. The trend 
test of the 49 patients with a known year of induction 
again failed to demonstrate any significant trends in 
the use of CT (P  = 0.6). 
CONCLUSION 
We observed a trend away from CT use in IBD. A dis-
connect appears to exist between expert opinion and 
evidence favoring CT with IFX and IMM, and evolving 
community practice.
Key words: Crohn’s disease; Ulcerative colitis; Infliximab; 
Azathioprine; Inflammatory bowel disease
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: In our 13 year experience at a community hospital 
infusion center, approximately 26% of inflammatory 
bowel disease patients receiving infliximab infusions 
received concomitant immunomodulator therapy. This is 
comparable to rates of combination therapy (CT) at major 
tertiary referral centers. However, there was a trend of 
decreased utilization of CT over the study period, even 
following the publication of SONIC. This suggests a 
need for further study to define the population with the 
most favorable risk-benefit ratio from CT, as well as the 
need for more direct guidelines from major societies. 
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INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) together 
comprise most cases of inflammatory bowel disease 
(IBD). The prevalence of IBD in the United States 
appears to be increasing, and it is currently estimated 
at 1 in 300 individuals, or roughly 1.5 million members 
of the population[1]. For both CD and UC, treatment of 
moderate to severe disease often includes the use of 
corticosteroids for induction of clinical remission, with 
guidelines recommending transitioning patients off 
corticosteroids and using an immunomodulator (IM) 
such as 6-mercaptupurine (6-MP), azathioprine (AZA) 
for either CD or UC, or methotrexate (MTX) for CD, 
to maintain remission[2] For those failing to maintain 
steroid free clinical response or remission with IM, the 
addition or substitution of the newer biologic therapies 
comprise the next step in what is now commonly 
referred to as a “step up” approach to IBD therapy. 
Infliximab (IFX) was introduced as the first biologic 
therapy targeting TNF-α. Initially approved in the United 
States for CD in 1997, approval for UC followed in 
2005[3]. Though IFX has been followed by other TNF-α 
inhibitors, and newer biologics targeting alternate 
pathways, IFX is still among the most widely used 
biologic therapies[4]. IFX and the other biologics are 
increasingly viewed as an alternative to steroid and IM 
therapy as part of a “top down” therapeutic approach, 
which has been shown to reduce patients’ steroid 
exposure as well as potentially improving overall clinical 
outcomes[5]. 
Early studies suggested a potential therapeutic 
benefit to combination therapy (CT) utilizing both IFX 
and IM, mainly through reduction of antibodies to IFX 
(ATI), reduced infusion reactions and higher IFX trough 
levels[6]. A major turning point was the SONIC study. 
While earlier work examined the role of IM combined 
with anti TNF-α mostly in those with IM exposure and 
failure prior to stepping up to IFX, SONIC focused on 
induction therapy among patients naïve to both biologic 
and IM with CD. Patients were randomized to receive 
either IFX, AZA or CT with both agents. CT was found to 
be superior to monotherapy with either IFX or AZA for 
the induction of steroid free clinical remission, without 
any increase in adverse events[7]. More recently the UC 
SUCCESS trial has demonstrated a similar benefit to 
combing AZA with IFX in those with UC[8]. 
Since the publication of SONIC, key thought leaders[9] 
and major society guidelines[10] have increasingly advo-
cated for the use of CT, but it is unclear to what extent 
community practice has changed, balanced against 
reports of opportunistic infections[11], and cases of hepa-
tosplenic T-cell lymphoma (HSTCL) with CT[12,13]. Currently, 
little is known regarding the adoption of CT in the 
community setting. Our main goal was to analyze the 
trends over time of CT usage for IBD overall, CD and UC. 
As a secondary goal we sought to examine whether the 
publication of the SONIC trial has had any impact on the 
proportion of CT use for CD in the community setting.
MATERIALS AND METHODS
The Northwell Health Center for Infusion Medicine, part 
of the Division of Rheumatology, provides IFX infusion 
services on behalf of both Northwell Health faculty 
and community gastroenterologists. Patients referred 
for IFX include both those beginning therapy at the 
center, as well as those switching their infusion therapy 
from another location. Center protocol requires that 
all physician referrals must include the completed 
standardized medical history form specifying IBD type, 
along with signed orders for IFX dose, schedule and pre-
infusion medications. The standardized form includes 
a medication history section which specifically asks the 
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referring physician to record either past or current use 
of AZA, 6-MP, MTX, without specifying dose, as well as 
other commonly used IBD medications. Following the 
initiation of IFX, updated versions of the standardized 
medical history are not performed. 
We conducted a retrospective chart review of all 
patients receiving IFX infusions at the center from 
01/01/2002 until 12/31/2014. Inclusion criteria required 
a diagnosis of CD, UC or indeterminate colitis (IC), receipt 
of at least 1 IFX infusion at the center, age of 18 years 
or greater, and availability of a completed standardized 
medical history form. 
In addition to IBD type, patients were subcategorized 
as induction or maintenance patients based on the 
schedule of the infusions they received. Induction patients 
were those whose first infusion was part of a documented 
standard week 0, 2, and 6 induction regimen. All other 
patients were grouped in the maintenance cohort. CT for 
both induction and maintenance patients was defined by 
IM use at first IFX dose at the infusion center. Descriptive 
analysis was performed of the overall group including 
both induction and maintenance IBD patients, as well 
as for the subgroup limited to induction patients. Similar 
analyses were performed by CD and UC subgroups. For 
the secondary analysis comparing usage of CT therapy 
pre vs post SONIC, a patient was considered a pre-
SONIC patient if they presented to the infusion center 
before April 2010. 
The proportions of CT use in the induction and mainten-
ance groups were calculated for all patients as well as 
for CD and UC separately. In secondary analyses we 
stratified patients based on years of age (< 35, 35-60, 
> 60), diagnosis (UC vs CD), gender and faculty status 
of the prescribing physician (faculty vs community) to 
investigate for any disparities in CT utilization between 
subgroups. 
RESULTS
The infusion records of 293 IBD patients were reviewed. 
Of these, 10 were excluded due to incompleteness of the 
infusion record, and 25 were excluded due to a missing 
record of concurrent medications, leaving 258 for analysis. 
The patients were referred by 57 gastroenterologists 
(mean and median patients per gastroenterologist of 
4.54 and 2 respectively). Patient demographics are 
detailed in Table 1. 154 (59.7%) had CD, 93 (36.1%) 
had UC. Eleven patients had IC, and these patients 
were included in the overall analysis but excluded from 
the disease-specific analyses. For two subjects, one 
each with CD and UC, infusion pre vs post April 2010 
was confirmed without exact date of first dose. These 
patients were excluded from the analyses of trends in 
CT use over time. 
All IBD patients
Among the total group of 258 patients with IBD, 60 
(23.3%) received CT at the time of first IFX infusion 
at our center. The Cochran-Armitage trend test of the 
256 patients with a known year of first infusion demon-
strated a significant decrease in the use of CT for all IBD 
patients over the 13 year period, from 2002 to 2014, 
p < 0.0001 (see Figure 1A). The IBD induction group 
included 133 patients of whom 35 (26.3%) received 
CT. The trend test of the 131 subjects in the IBD 
induction group with a known year of induction again 
demonstrated a significant decreasing trend in the use 
of CT, p = 0.0024. 
For the 258 total IBD group 111 (43.0%) had their 
induction or maintenance regimen start pre-SONIC 
compared with 147 (57.0%) post-SONIC. Due to 
evidence of effect modification (EM) of the patient’s IBD 
diagnosis type on the relationship between induction 
time period (pre vs post-SONIC trial) and use of CT (p 
= 0.01), analyses comparing pre vs post-SONIC trial 
were stratified by disease type. Stratum-specific results 
for CD are reported below. 
CD patients
Among the 154 patients with CD, 37 (24.0%) received 
CT at the time of first infusion. The Cochran-Armitage 
trend test of the 153 patients with a known year of 
first infusion demonstrated a significant decrease in the 
use of CT over the 13 year period, from 2002 to 2014, 
p < 0.0001 (see Figure 1B). The CD induction group 
included 77 patients of whom 20 (26.0%) received CT. 
The trend test of the 76 subjects with a known year of 
induction again demonstrated a significant decreasing 
trend in the use of CT, p = 0.0024. The proportion of 
all CD patients receiving CT was greater pre vs post-
SONIC (43.8% vs 7.4%, respectively, p < 0.0001) as 
well as for the induction only group (40.0% vs 10.8%, 
respectively, p = 0.0035).
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Table 1  Patient demographics n  (%)
IBD1 CD UC
Total 258 154 93
Male  127 (49.2) 78 (50.6) 48 (51.6)
Mean age, yr 40.88 ± 16.67 39.59 ± 16.28 43.66 ± 17.04
IFX Pre-SONIC 111 (43.0) 73 (47.4) 30 (32.2)
6-MP/AZA use   56 (21.7) 35 (22.7) 18 (19.4)
MTX use   4 (1.6) 3 (1.9) 1 (1.1)
1The “IBD Total” group includes the “CD Total” and “UC Total” groups, as well as 11 patients with indeterminate colitis. IBD: Inflammatory bowel disease; 
CD: Crohn’s disease; UC: Ulcerative colitis; IFX: Infliximab; 6-MP: 6-mercaptupurine; AZA: Azathioprine; MTX: Methotrexate.
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DISCUSSION
Despite the positive effects offered by CT for CD in the 
SONIC population, and for UC by UC SUCCESS, it is 
unclear to what degree the use of CT has been adopted 
into clinical practice. A recent review from 7 high 
volume IBD referral centers, comprising 1659 patients 
with CD and 946 with UC, showed a wide range of 
adoption of CT. Among CD patients the use CT overall 
was 21%. There was a significant variation of usage 
across all centers ranging between 8% and 32%, with 
a 95%CI: 3.15 (1.79-5.56). Among UC patients the 
use of CT overall was 9%, with no significant variation 
of usage seen, ranging between 6% and 13%, CI 1.14 
(0.48-2.78)[14].
Our findings offer a different perspective by which 
to view the question of CT usage, by providing 13 years 
of follow up data addressing the adoption of CT in the 
community setting. Examining a mixed cohort of 258 
patients of whom 154 had CD, all receiving IFX, we 
found that CT was employed at the beginning of therapy 
in 23.3% of patients overall. Notably, we observed a 
significant trend of decreasing use of CT for IBD generally, 
in the CD cohort, as well as for the subgroup of CD 
patients receiving induction therapy. 
Much like the findings from the referral center 
consortium, we suspect that these findings do not reflect 
a lack of awareness on the part of community gastro-
enterologists with the SONIC trial. More likely, it reflects 
a deeper understanding of what the SONIC results 
specifically support; the value of CT in a subset of 
treatment naïve patients. It is also likely that persistent 
concerns regarding adverse events with CT exert a 
strong pull away from CT even in cases where it may be 
appropriate. Though it is still uncertain if CT increases 
Non-Hodgkin’s Lymphoma rates overall as compared 
to thiopurine monotherapy[15], it is now accepted that 
CT increases the risk of Hepatosplenic T Cell Lymphoma 
(HSTCL). While exceedingly rare, a recent systematic 
review found that 20 of 36 documented cases of HSTCL 
occurred in patients with a history of CT use[13]. Evidence 
of this association began to accumulate in 2007, which 
coincides with the temporary disappearance of CT use 
for our patients at that time[16]. Despite risk-benefit 
analyses favorable to CT accounting for lymphoma[17] 
- the preferences of physicians and/or patients have 
likely been impacted, particularly when faced with a 
black box warning addressing HSTCL found in the IFX 
packaging insert. Even if one is to accept the benefit of 
CT for induction, there is still uncertainty regarding the 
appropriate duration of IMM for maintenance[18]. This 
uncertainty may itself serve as a barrier to choosing CT 
over anti-TNF-α monotherapy. 
The main weaknesses of our findings are mainly 
those which are inseparable from the retrospective 
study design. While our primary aim was simply obser-
vational, examining trends of CT usage over time, we 
specifically singled out the publication of SONIC as 
a time point for analysis and comparison. Given the 
UC patients
Among the 93 patients with UC, 19 (20.4%) received 
CT at the time of first infusion. The Cochran-Armitage 
trend test of the 92 patients with a known year of first 
infusion did not demonstrate any significant trends in 
the use of CT over time, p = 0.9 (see Figure 1C). The UC 
induction group included 50 patients of whom 14 (28.0%) 
received CT. The trend test of the 49 patients with a 
known year of induction again failed to demonstrate any 
significant trends in the use of CT, p = 0.6. 
There were no statistically significant differences in 
the proportions of CT use across the study period, among 
CD patients or UC patients, according to age group, 
gender, faculty status of the referring gastroenterologist, 
use of other agent or steroid use (p > 0.05 for all tests); 
results not shown. 
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Figure 1  Percentage of inflammatory bowel disease (A), Crohn’s disease 
(B), and ulcerative colitis (C) patients on combination therapy. Y axis: 
Percentage of infusion patients receiving combination therapy (0-100%); X 
axis: Year for which data is being reported (2002-2014). A: Percentage of 
inflammatory bowel disease patients receiving combination therapy over time; 
B: Percentage of Crohn’s disease patients receiving combination therapy over 
time; C: Percentage of ulcerative colitis patients receiving combination therapy 
over time.
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Applications
The decline in CT utilization highlights the need for further studies to define the 
ideal patient population for CT, as well as the need for more definitive guidelines 
from professional societies. 
Terminology
Combination therapy refers to the concurrent use of an immunomodulator, such 
as azathioprine, with a biologic drug, such as infliximab, in the treatment of 
inflammatory bowel disease.
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benefit of CT observed in the SONIC cohort are the daily 
concerns of both patients and their physicians regarding 
HSTCL risk and the uncertainty of optimal duration of 
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benefit in non treatment native patients, will be needed 
to support any future expanded use of CT. 
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Background
The SONIC trial demonstrated the superiority of combination immunomodulator 
and biologic therapy for Crohn’s disease (CD). Further studies evaluated the 
efficacy of combination therapy (CT) in ulcerative colitis. There are concerns 
regarding the safety of CT, specifically the risks of infection and malignancy.
Research frontiers
Little is known about the degree of utilization of CT in the community setting. It 
is also unknown whether the publication of the SONIC trial impacted rates of 
CT usage. 
Innovations and breakthrough
This study demonstrates that the utilization of CT has generally trended down 
over the past decade. It also demonstrates that the publication of the SONIC 
study did not lead to an increase in the utilization of CT.
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